SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Reimbursement models to tackle market failures for antimicrobials: Approaches taken in France, Germany, Sweden, the United Kingdom, and the United States
3 references·0 citing·12 second hop
Reimbursement models to tackle market failures for antimicrobials: Approaches taken in France, Germany, Sweden, the United Kingdom, and the United States (2020)Reimbursement models to tackle market fai…Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies (2019)Comparison of Sales Income an…Shortages of benzathine penicillin for prevention of mother-to-child transmission of syphilis: An evaluation from multi-country surveys and stakeholder interviews (2017)Shortages of benzathine penic…Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach (2016)Antibiotic reimbursement in a…Why is big Pharma getting out of antibacterial drug discovery? (2003)A comprehensive regulatory framework to address the unmet need for new antibacterial treatments (2013)Repairing The Broken Market For Antibiotic Innovation (2015)Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality (2016)Introduction and geographic availability of new antibiotics approved between 1999 and 2014 (2018)Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010–2020 (2021)Clinical development success rates for investigational drugs (2014)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 (2017)Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries (2019)Medicine Shortages: Gaps Between Countries and Global Perspectives (2019)The pros and cons of reshoring to address the problems of shortages in global pharmaceutical value chains: the case of antibiotics (2022)
this work references cited by second hop

References

  • 2017Shortages of benzathine penicillin for prevention of mother-to-child transmission of syphilis: An evaluation from multi-country surveys and stakeholder interviews175 cited
  • 2016Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach113 cited
  • 2019Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies90 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work